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Malaria parasites are subjected to high levels of oxidative
stress during their development inside erythrocytes and the
ability of the parasite to defend itself against this assault is crit-
ical to its survival. Therefore,Plasmodiumpossesses an effective
antioxidant defense system that could potentially be used as a
target for the development of inhibitor-based therapy.We have
identified an unusual peroxiredoxin protein that localizes to the
nucleus of Plasmodium falciparum and have renamed it PfnPrx
(PF10_0268, earlier calledMCP1).Ourwork reveals that PfnPrx
has a broad specificity of substrate being able to utilize thiore-
doxin and glutaredoxin as reductants and having the ability to
reduce simple and complex peroxides. Intriguingly, chromatin
immunoprecipitation followed by deep sequencing reveals that
the enzyme associates with chromatin in a genome-wide man-
ner with a slight enrichment in coding regions. Our results rep-
resent the first description of a dedicated chromatin-associated
peroxiredoxin and potentially represent an ingenious way by
which the parasite can survive the highly oxidative environment
within its human host.
Malaria is one of themost common infectious diseases in the
world with500 million cases each year and one to three mil-
lion deaths (1). The disease has an enormous burden on human
health and causes decreased productivity and economic growth
and increased poverty (2). The lack of an effective vaccine, the
emergence of resistance to first-line drugs such as chloroquine
and antifolates and recent reports of clinical cases of reduced
susceptibility to artemisinin in Cambodia (reviewed in Ref. 3),
combined with the small number of suitable new drugs against
the malaria parasite demonstrate the need to identify potential
new targets.
The malaria-infected erythrocyte is under constant attack
from reactive oxygen and nitrogen species. These are produced
exogenously by the host immune system in response to infec-
tion, or endogenously by the generation of redox-active by-
products resulting from the high metabolic rates of the multi-
plying parasite and the degradation of large quantities of
hemoglobin (4). The ability of Plasmodium falciparum to pro-
tect itself against oxidative damage is thus critical and the par-
asite possesses multiple biochemical pathways able to mediate
antioxidant defense and redox regulation (5, 6). P. falciparum
lacks catalase and a genuine glutathione peroxidase and there-
fore relies heavily on peroxiredoxins for the reduction of reac-
tive oxygen species and reactive nitrogen species (7).
Peroxiredoxins (Prx) are a family of thiol-dependent peroxi-
dases known to reduce and scavenge hydroperoxides and thus
form an important part of the cellular antioxidant machinery.
Most peroxiredoxins contain at least one cysteine residue in
their active site and because of its ability to react with the per-
oxide substrate it is referred to as the peroxidatic cysteine. This
residue is the defining feature of this class of enzymes also
referred to as AhpC-TSA5 family (8) The reaction results in the
formation of a sulfenic acid intermediate that is usually reduced
by the resolving cysteine present in the 2-Cys peroxiredoxins.
The inter- or intramolecular disulfide bond formed can be
reduced by thioredoxin, glutaredoxin or glutathione depending
on the substrate specificity of the respective peroxiredoxin. For
instance, mammalian 2-Cys peroxiredoxin 1 can only react
with thioredoxin and does not accept glutaredoxin or thiore-
doxin as substrates (9, 10).
Apart from their role as antioxidants, the proteins are also
known to function as redox sensors in response to oxidative
stress. They have also been implicated in cellular processes such
as apoptosis, cell proliferation and differentiation (11). This
functional diversity can be attributed to their structural flexi-
bility, which leads to the association of the dimers to high Mr
oligomeric proteins or vice versa, the susceptibility of one of
their active site cysteines to hyperoxidation by their peroxide
substrates and their high abundance in the cell (12). In addition,
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it was shown that the phosphorylation of peroxiredoxins affects
their subcellular distribution and enzymatic activity (13).
Usually organisms contain more than one peroxiredoxin,
which are found in different subcellular locations such as cyto-
sol,mitochondria, peroxisomes, andnucleus (8). This is also the
case for Plasmodium. To date, five malarial peroxiredoxins
have been characterized: cytosolic PfTrx-Px1 and mitochon-
drial PfTrx-Px2 (14–16), cytosolic PfTrx-Px3 (17, 18), PfAOP,
potentially localizing to the apicoplast (19), and finally a gluta-
thione-dependent-like peroxidase with a preference for thiore-
doxin as reducing substrate (7). P. falciparum also possesses
several proteins belonging to the thioredoxin superfamily,
which provide reducing equivalents to the peroxiredoxins
(reviewed in Ref. 6).
In addition to the five characterized peroxiredoxins, the
malaria parasite possesses an additional protein with a con-
served AhpC-TSA domain called MCP1 (merozoite capping
protein-1, PF10_0268) (20, 21). MCP1 was described as a cyto-
solic protein localizing to the invasion tight junction, a zone of
tight apposition between the merozoite and the red blood cell
membrane formed during the invasion process (20). However,
it is not known whether the AhpC-TSA domain of MCP1 is
functional (20, 21). Additionally, MCP1 has two other defined
domains with a negatively charged middle region enriched in
glutamate and aC-terminal positively charged section enriched
in lysine. It was speculated from the solubility properties of
MCP1 and the C-terminal lysine-rich domain that this region
may be required for binding to the cytoskeleton within the
invading merozoite (21).
In this work, we show that MCP1 is a peroxiredoxin with
unusual biochemical characteristics. As this enzyme exclu-
sively localizes to the nucleus (in contrast to previous reports)
we renamed it PfnPrx (P. falciparum nuclear peroxiredoxin). In
addition, we demonstrate that PfnPrx is associated with the
chromatin of the parasite in a genome-widemanner, suggesting
a potentially essential role in the protection of nuclear DNA
against oxidative stress.
EXPERIMENTAL PROCEDURES
Parasite Cultures—P. falciparum asexual stage parasites
were maintained in human erythrocytes (blood group O) at a
hematocrit of 4%with 0.5% (w/v)AlbumaxTM (Invitrogen) (22).
P. falciparum 3D7 parasites were originally obtained from
David Walliker at Edinburgh University. Cultures were syn-
chronized as described previously (23).
Antisera—Rabbit and mouse antibodies were generated
against PfnPrx1–100, containing the conserved oxidoreductase
domain, from a GST fusion protein expressed from a plasmid
construct using the following primers: PfnPrxF (5-CGCGG-
ATCCATGGCTCAATTAGCAGAAAATAC-3) and PfnPrxR
(5-CCGCTCGAGTAAGGAAGTTCTAGCTTTTC-3. PCR
products were digested with BamH1/Xho1 (underlined letters
in primers), purified and cloned into the plasmid pGEX4T-1
(Amersham Biosciences). For immunoblots, saponin-lysed
parasite pellets from highly synchronous 3D7 parasites were
separated in sample buffer on 4–12% (w/v) SDS-NuPAGE gels
(Invitrogen) under reducing conditions and transferred to
nitrocellulose membranes (Schleicher & Schuell). Affinity
purified PfnPrx rabbit anti-serum and anti-PfnPrx mouse
monoclonal were diluted in 0.1% (v/v) Tween 20-phosphate-
buffered salinewith 1% (w/v) skimmilk. Appropriate secondary
antibodies were used, and immunoblots were developed by
ECL (Amersham Biosciences). For the time course of expres-
sion analysis, proteins extracted from an equal number of cells
were used for each time point.
Fluorescence Imaging—Fluorescence images of parasites
were captured using a Carl Zeiss Axioskop microscope with a
PCO Sensicam and Axiovision software (version 2). For immu-
nofluorescence assays of free and/or invading merozoites,
highly synchronous schizont stage 3D7 parasites in the process
of rupture/reinvasion were smeared and fixed in 100% metha-
nol at20 °C. After blocking in 3% (w/v) bovine serumalbumin
(Sigma), the cells were incubated for 1 h with the appropriate
antisera: rabbit anti-PfRON4 (1/200) (24, 25), mouse monoclo-
nal anti-PfnPrx (1/200). Bound antibodies were then visualized
with Alexa Fluor 488/594 anti-rabbit IgG or anti-mouse IgG
(Molecular Probes) diluted 1:1000. Parasites were mounted in
Vectashield (Vecta Laboratories) containing DAPI (Roche
Molecular Biochemicals).
Immunoelectron Microscopy—Parasites for electron micros-
copy immunolabeling were fixed and prepared as described
previously (26). The primary antibody used was the rabbit anti-
PfnPrx. Samples were washed and incubated with secondary
antibodies conjugated to 15-nm colloidal gold (BB Interna-
tional). Sampleswere then post-stainedwith 2% aqueous uranyl
acetate then 5% triple lead and observed at 120 kV on a Philips
CM120 BioTWIN Transmission Electron Microscope.
Vector Construction, Transfection, and Southern Blotting—
To create the plasmid used for the integration of GFP at the 3
end of the nPrx gene by single crossover, a PCR fragment con-
taining exon 3 of nPrxwithout a stop codonwas cloned into the
BglII-AvrII sites of the pARL1-GFP vector (27, 28). Parasites
were transfected, and integrantswere selected as described pre-
viously (27). Integration was monitored by Southern blots
according to standard procedures.
Protein Purification andEnzymatic Assays—APCR fragment
containing nucleotides 1 to 492 of PfnPrx was amplified from
P. falciparum cDNA and cloned in the BamH1-Xho1 site of the
pET-45b expression vector (Novagen). The latter directs
expression of the protein with an N-terminal His6 tag to facili-
tate purification of the recombinant protein. Generation of the
nPrxC56S mutant was performed by site-directed mutagenesis
with the QuikChange II XL kit from Agilent Technologies.
Induction and purification of His6-nPrx1–164 were performed
according to standard procedures. P. falciparum TrxR and
PfTrx1 were generated as described (29, 30). P. falciparum glu-
taredoxin 1 (PfGrx1, PFC0271c) was amplified from 3D7
genomic DNA and cloned in the BamH1-Xho1 site of the pET-
45b expression vector (Novagen). Induction of the protein was
performed at 27 °C overnight.
The overall antioxidant activity of PfnPrx was estimated by
analyzing its ability to protect Escherichia coli glutamine syn-
thetase (Sigma) from inactivation by a thiol-metal catalyzed
oxidation system (DTT/Fe3/O2) (31). The P. falciparum nPrx
kinetic parameters were determined (30) using a spectrophoto-
metric assay to determine the initial rates of the peroxidase
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reaction as described previously for Toxoplasma gondii Trx-
Px2 (30, 32). For the assays using the thioredoxin system, the
reaction mix contained 100 mM HEPES, pH 7.6, 1 mM EDTA,
0.25 units of P. falciparum thioredoxin reductase, 2M PfnPrx,
200MNADPH, varying concentrations of P. falciparum cyto-
solic thioredoxin PfTrx1 (20–100M) at a constant concentra-
tion of 20 M hydrogen peroxide.
For assays using the GSH system with P. falciparum Grx1,
the reaction mix contained 100 mM HEPES, pH 7.6, 1 mM
EDTA, 0.5 units glutathione reductase, 1 mM GSH, 2 M PfnPrx,
200MNADPH, varying concentrations of P. falciparum cyto-
solic glutaredoxin PfGrx1 (1–30 M) at a constant concentra-
tion of 20 M hydrogen peroxide or varying concentrations of
hydrogen peroxide (1–50 M) and cumene hydroperoxide
(1–100 M) at a constant concentration of 10 M PfGrx1. No
NADPH oxidation was observed without addition of PfGrx1
indicating that PfnPrx cannot be reduced by GSH itself. The
decrease in absorbance at 340 nmdue toNADPHoxidationwas
determined over 30 s with time points taken every 10 ms.
Assays were performed at 25 °C. The linear rates were deter-
mined and fitted to the Michaelis-Menten equation using
Graphit (version 5.0; Erithracus).
Chromatin Immunoprecipitation and Deep Sequencing—
Chromatin immunoprecipitation of nPrx-GFP from formalde-
hyde cross-linked and sonicated chromatin was performed as
described (33) using an anti-GFP antibody (AbCam 290).
Immunoprecipitated as well as input chromatin was decross-
linked at 45 °C in the presence of 0.5 M NaCl and tested by
quantitative PCR (for primer list, see supplemental Table 1) or
used for Illumina sequencing library preparation according to
the linear amplification protocol (34). Sequencing libraries
were loaded on the Illumina Genome Analyzer IIx and
sequenced for 36 cycles from one side of the fragments. The
quality filtered 35-bp sequence reads were mapped against the
P. falciparum genome assembly (PlasmoDB version 6.1) using
the standard Illumina pipeline. Coverage plots were generated
using uniquelymapped sequence reads by counting the number
of overlapping tags in 100-bpwindows and visualized in Signal-
Map (NimbleGen). The ratio trackwas obtained by dividing the
ChIP-seq tag counts with the input tag counts and displayed on
a log2 scale. For generation of average gene profile the coding
body of all “normal size” genes (1–10 Kb) were divided into 20
equal size windows and five 150-bp windows immediately up-
or downstream represented flanking sequences. The ratios of
the tag counts in the ChIP versus input data set has been com-
puted in each individual windows and averaged in the corre-
sponding window of all genes. For scatter plot analysis, the
ratios of ChIP and input tag counts have been calculated in the
coding body of each gene have been plotted against the RNAseq
tag density (tag/1000 bp transcript) of an independent 3D7 sch-
izont population (34).
RESULTS
Identification of PfnPrx (Earlier MCP1) as a Nuclear
Peroxiredoxin—To investigate the role of PfnPrx (MCP1) in the
merozoite invasion process, we generated an antibody against
FIGURE 1. PfnPrx is expressed throughout the erythrocytic stage. A, domain organization of PfnPrx PF10_0268. The alignment shows the conserved
AhpC-TSA family domain with the peroxidatic cysteine. Comparison was realized with Praline software. The GenbankTM accession numbers of the aligned
sequences are as follows: PfnPrx, AAC46600; Saccharomyces cerevisiaeDOT5, P40553; PfTPx1, XP_001348542; PfTPx2, XP_001350554; Pf1-Cys_Prx, AAG14353;
andPfAOP, AY306209. Theasterisks represent conserved residues, and thearrowhighlights theperoxidatic cysteine.B, time courseof PfnPrx expressionduring
the blood stage using an affinity-purified rabbit anti-serum raised against the first 100 residues of PfnPrx.
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the conserved oxidoreductase domain (Fig. 1A) (20). Western
blots on schizont stage protein extracts showed a single specific
band of55 kDa, which was slightly higher than the predicted
45 kDa (Fig. 1B, 48 h lane) and is in agreement with previous
results (20). All of the other P. falciparum peroxiredoxins
having sizes between 22 and 28 kDa, we can be confident that
our antibody is not cross-reacting with any of them.We next
performed a time course analysis for expression of PfnPrx
(MCP1) using parasite protein extracts taken at 8-h intervals
throughout the erythrocytic asexual cycle. The PfnPrx
(MCP1) protein was present as a single 55 kDa band in all
samples analyzed with the highest expression between 32 to
48 h (Fig. 1B) which corresponds to the schizont stage where
the parasite undergoes nuclear division and also when pro-
teins involved in merozoite invasion are expressed. This pat-
tern is also in agreement with the RNA expression analyses
published previously (35).
To determine the subcellular localization of the PfnPrx
(MCP1) protein, we performed immunofluorescence assays on
parasites from different stages of the erythrocytic cycle. The
anti-nPrx (MCP1) monoclonal antibody overlapped almost
completely with the DAPI-stained parasite DNA in rings, tro-
phozoites, and schizonts, suggesting that PfnPrx was located in
the nucleus (Fig. 2A), a subcellular localization different to that
described previously (20). Analysis of the protein sequencewith
the PredictProtein software (36) also revealed a potential
nuclear localization signal in the C terminus of PfnPrx
(KKPAKKVVKKK). To analyze the subcellular localization of
PfnPrx (MCP1) in more detail, we performed immunofluores-
cence experiments on merozoites during erythrocyte invasion
FIGURE 2. PfnPrx is a nuclear protein. A, immunofluorescence using themousemonoclonal anti-PfnPrx antibody demonstrates localization of PfnPrx in the
nucleus throughout the erythrocytic stage. Troph, trophozoite. B, PfnPrx does not localize to the tight junction of merozoites in the process of invasion.
Immunofluorescence with mouse monoclonal anti-nPrx and rabbit anti-RON4 antibody shows that PfnPrx is restricted to the nucleus in parasites invading a
red blood cell. C, immunoelectron microscopy using the rabbit anti-PfnPrx antibody on schizont stage parasites reveals that PfnPrx is in the electron dense
nuclear periphery. The image shows a single merozoite located within a schizont.
AMalarial Nuclear Peroxiredoxin
APRIL 1, 2011•VOLUME 286•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 11749
 at G
lasgow University Library, on Decem
ber 1, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
in which we observed that PfnPrx also localized to the nucleus
of the parasite. No anti-PfnPrx (MCP1) signal was found at the
tight junction, visualized by staining with an antibody against
the RON4 protein, a well characterizedmarker of this transient
structure (25). To determine whether this localization was due
to our antibody recognizing a protein other than PfnPrx
(MCP1), we engineered a parasite line in which the green fluo-
rescent protein (GFP) gene was integrated by single crossover
at the 3 end of the PfnPrx (MCP1) gene leading to the produc-
tion of a fluorescent PfnPrx (MCP1) (Fig. 3, A and B). Western
blot analysis showed that PfnPrx (MCP1) was detected as an
80-kDa protein with both the PfnPrx (MCP1) mouse monoclo-
FIGURE 3.Endogenously taggingnPrx confirms its status as anuclear protein.A, schematic of the strategy employed togenerate the 3D7nPrx-3GFP line.
hDHFR, human dihydrofolate reductase. B, Southern blots confirming integration of the targeting construct at the endogenous nPrx locus. C, Western blots
using themousemonoclonal anti-nPrx or an anti-GFP antibody confirms that the 3D7nPrx-3GFP parasite line expresses the nPrx-GFP chimera.D, epifluores-
cence microscopy on the 3D7nPrx-3 GFP line demonstrates that the tagged nPrx localizes to the nucleus in all blood stages. X-over; crossover.
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nal antibody or an anti-GFP monoclonal antibody confirming
expression of the chimeric protein and providing additional
evidence for the specificity of ourmousemonoclonal anti-nPrx
antibody (Fig. 3C). To determine the localization of the PfnPrx-
GFP fusion, the 3D7 PfnPrx-GFP line was analyzed by epifluo-
rescence microscopy. As shown in Fig. 3D, the PfnPrx-GFP
fluorescence overlaps with the DAPI-stained parasite DNA in
rings, trophozoites, and schizonts confirming that nPrx
(MCP1) is found in the nucleus of the parasite throughout the
blood stage cycle. To determinemore precisely the localization
of PfnPrx in the nucleus, we performed immunoelectron
microscopy on P. falciparum schizont stage sections. PfnPrx
localizes predominantly to the more electron dense regions at
the nuclear periphery, and this is believed to represent hetero-
chromatin (Fig. 2C) (37). Consequently, because of the nuclear
localization and functional data presented below, we renamed
this protein PfnPrx (P. falciparum nuclear peroxiredoxin).
PfnPrx Is a Peroxiredoxin with Unusual Characteristics—
PfnPrx possesses anN-terminal conservedAhpC-TSAdomain.
To investigate its functionality, the N-terminal portion of the
FIGURE4.PfnPrx is aperoxiredoxinwithunusual characteristics.A, purificationof theN-terminal domainof PfnPrx.B, glutamine synthetase (GS) protection
assays revealing that PfnPrx is an antioxidant protein and that this activity was dependent on its conserved peroxidatic cysteine. C–E, peroxidase assays
showing that glutaredoxin (C) is a potent reductant of PfnPrx and that PfnPrx efficiently reduces hydrogen peroxide (D) and cumene hydroperoxide (E). 2 M
PfnPrxwas used for all assays, 20Mhydrogen peroxidewas used for the variable Pf glutaredoxin 1 assay, and 10MPfGrx1was used for the variable peroxide
assays. Results are representative of at least three independent experiments.
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protein (amino acids 1–164) was recombinantly expressed and
purified (Fig. 4A), and its potential peroxidase activity was
assessed using various enzymatic assay systems. Initially, we
determined whether the protein protects glutamine synthetase
from inactivation by a thiol-metal catalyzed oxidation system
(DTT/Fe3/O2) (31). 4.5g of the recombinant peroxiredoxin-
like domain of PfnPrx rescues glutamine synthetase activity by
50% (Fig. 4B), confirming that the AhpC-TSA domain was cat-
alytically active, therefore suggesting that PfnPrx has antioxi-
dant capacity. The specificity of this catalytic activity was fur-
ther investigated by exchanging the predicted active site
cysteine residue at position 56 by serine, which totally abolished
the glutamine synthetase protection activity of the recombi-
nant protein (Figs. 1A and 4B). The fact that the recombinant
AhpC-TSA domain of PfnPrx showed the ability to protect glu-
tamine synthetase activity is presumably attributable to its
capacity to reduce hydrogen peroxide. This suggests that this
part of the protein acts as a peroxidase that might potentially
protects nuclear components such as DNA from oxidative
insults. To identify its natural reducing substrate, the catalytic
activity of PfnPrx was analyzed in the presence of P. falciparum
thioredoxin 1, glutathione, and glutaredoxin 1. PfnPrx had the
ability to reduce hydrogen peroxide, and this activity increased
with increasing concentrations of PfTrx1 without reaching sat-
uration at concentrations as high as 100 M (supplemental Fig.
1), suggesting that ismost likely not the favored reductant of the
enzyme.
In addition to the thioredoxin system, P. falciparum pos-
sesses a functional glutathione system, and we studied the pos-
sibility that it could be involved in the reduction of PfnPrx. No
PfnPrx peroxidase activity on hydrogen peroxide was detected
when using GSH as a reductant, whereas addition of glutare-
doxin 1 (PfGrx1 (15)) to the assay mix supported the reduction
of PfnPrx with saturation kinetics (Fig. 4C) and a reasonable
reaction rate. At a concentration of 20 M H2O2, the apparent
Km for PfGrx1was determined to be4M, showing that it was
an excellent reductant for PfnPrx. When looking at the affinity
of PfnPrx for H2O2, an apparent Km of 14 M was calculated
when 10 M of PfGrx1 was used (Fig. 4D), demonstrating that
H2O2 was a good substrate for PfnPrx and corroborating the
results obtained with the glutamine synthetase protection
assay. In addition, PfnPrxwas able to reduce cumene hydroper-
oxide with an apparent Km of 30 M (Fig. 4E). The specific
activity of the recombinant protein was in the range of 6 mol/
min/mg protein, which is low compared with the activity of
other Plasmodium peroxiredoxins (16, 30). It cannot be
excluded that regulatory or structural features important to
define substrate specificity are missing from the recombinant
PfnPrx given that only the AhpC-TSA domain of PfnPrx rather
than the full-length protein was analyzed.
As PfnPrx is localized to the nucleus, it would be expected
that its favored physiological reductant should also localize to
this organelle or at least have the ability to translocate to it from
the cytoplasm upon oxidative stress. To investigate the cellular
localization of PfGrx1, we generated parasites expressing a
PfGrx1-GFP fusion. PfGrx1-GFP mostly localizes to the cyto-
plasm of the parasite though some of protein overlaps with the
DAPI-stained nuclear DNA, suggesting that it has the ability to
translocate between the two compartments (supplemental Fig.
2). However, we cannot at this stage exclude that the nuclear
staining is the result of a mislocalization of the fusion protein
due to its overexpression from an episome.
Having demonstrated that PfnPrx had the ability to detoxify
peroxides in vitro, we hypothesized that it could potentially be
involved in protecting the nucleus of the parasite from oxida-
tive stress. However, it has not been possible to demonstrate a
consistent increase in the level of PfnPrx transcript or protein
when submitting the parasites to exogenous oxidative stress in
vitro using a glucose/glucose oxidase system (data not shown).
PfnPrx Is Potentially Essential in Erythrocytic Stage—To gain
further insight into the role of PfnPrx in the blood stage cycle of
themalaria parasite, we attempted to generate a knock-out line
in both P. falciparum and Plasmodium berghei, a rodent
malaria parasite often used as amodel for humanmalaria due to
the ease with which knock-out strains can be generated.
Despite several attempts, we were unable to generate a nPrx
knock-out line in either of the Plasmodium species tested. This
was in contrast with the ability to easily tag the PfnPrx with
GFP, suggesting that the protein performs an essential/impor-
tant function in the erythrocytic stage of the malaria parasite
(data not shown).
ChIP-seq Analysis Reveals Genome-wide Binding of PfnPrx to
Chromatin—The co-localization of PfnPrx with the DAPI-
stained DNA suggested that it was potentially associating with
chromatin. To investigate this possibility, we performed a
genome-wide ChIP-seq analysis on schizont stage 3D7nPrx-
GFP parasites using an anti-GFP antibody. Intriguingly, visual
inspection of the data showed nearly even distribution of
PfnPrx across the P. falciparum genome (Fig. 5A). An obvious
exception was the strong depletion of PfnPrx from the centro-
meric regions (Fig. 5B). In addition, PfnPrx was found to be
slightly enriched in the coding body of genes (Fig. 5B), which
was also apparent on the average gene profile (Fig. 5C). Enrich-
ment of PfnPrx in coding regions and its depletion from cen-
tromeres were confirmed by ChIP-quantitative PCR and were
found to be consistent across all stages of intraerythrocytic
development (Fig. 5D). Importantly, recoveries with the GFP
antibody for chromatin isolated from nontagged 3D7 parasites
were very low for all sites tested, proving the specificity of our
assay (data not shown). Finally, we determinedwhether enrich-
ment of PfnPrx showed a correlationwith transcriptional activ-
ity. As demonstrated by scatter plot analysis (Fig. 5E), PfnPrx
occupancy in coding regions showed limited variation across
genes and no or minimal correlation with steady state mRNA
levels. Notably, outlier genes with high PfnPrx occupancy
tended to be tRNA or rRNA genes. In conclusion, the ChIPseq
data demonstrates the intimate association of PfnPrx with the
malaria genome.
To determine whether the association of PfnPrx with the
chromatin was mediated through interactions with other pro-
teins, we performed immunoprecipitation on the 3D7nPrx-
GFP line using an anti-GFP antibody. Mass spectrometry anal-
ysis revealed, in addition to nPrx-GFP, a high number of
different proteins such as core histones, heat shock proteins,
proteasome components, and a few transcription factors, but
none with very high peptide coverage (Fig. 6). This high variety
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FIGURE5.PfnPrxshowsgenomewidechromatinassociation.AandB, broaddistributionofPfnPrx (A), its enrichment in codinganddepletionat centromeric
region (B) demonstratedby coverageplots and ratio trackof PfnPrx-GFPChIP-seqdataobtained fromschizont stageparasites.C, averagegeneprofile of PfnPrx
occupancy.D, quantitative PCR data confirming enrichment of PfnPrx in coding region and its depletion at centromeres at three different stages of intraeryth-
rocytic development. E, scatter plot analysis of correlation between PfnPrx enrichment in coding body of genes and steady state mRNA levels (RNA-seq data
of schizont stage parasites from Bartfai et al. (33)).
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of proteins was somewhat expected based on the scale of the
broad association of nPrx with the genome and the absence of
any clear specific interactor suggests that nPrx might interact
directly with the chromatin, potentially through its highly pos-
itively charged C terminus as has been shown for proteins such
as linker histone H1 (38).
DISCUSSION
MCP1was previously described as a protein localizingwithin
the cytoplasmof themerozoite and associatingwith themoving
junction as the parasite invades the host erythrocyte (20, 21). It
was noted that this protein contained an oxidoreductase
domain, although it had not been demonstrated to be func-
tional. In contrast to the previous observation we show here
that MCP1 is exclusively localized within the nucleus of P. fal-
ciparum.Moreover, we demonstrate that the protein contains a
functional peroxiredoxin domain with unique characteristics.
Consequently, we have renamed the protein PfnPrx. The func-
tional properties of PfnPrx as a peroxiredoxin, its subcellular
localization within the nucleus, its coverage of a large propor-
tion of P. falciparum chromosomes, and our inability to inacti-
vate its gene in two different species of Plasmodia suggest that
it plays an important role in this compartment.
Peroxiredoxins are a family of anti-oxidants that protect the
cell from metabolically produced reactive oxygen species. The
P. falciparumPfnPrx prefers glutaredoxin over thioredoxin as a
reducing substrate and shows saturation kinetics. The protein
reduces hydrogen peroxide and cumene hydroperoxide equally
well, suggesting that it does not discriminate between anor-
ganic or organic hydroperoxides. Its specificity for glutaredoxin
as a reducing substrate is unusual especially becausemost other
known peroxiredoxins or peroxiredoxin-like proteins react
with thioredoxin or glutathione. Peroxiredoxins with this sub-
strate specificity have so far only been described in plants,
although some of these can also be reduced by thioredoxins (9,
39, 40, and reviewed in Ref. 41)). Intriguingly, PfnPrx was asso-
ciated strongly with the genome of the parasite, suggesting that
the protein has a role in either protecting nuclear components
such asDNA fromoxidative damage or being involved inmain-
taining chromatin structure, DNA repair, or mechanisms that
affect transcriptional activities. In fact, it has been shown that
redox active thiol-containing proteins and peptides are critical
for these processes because they can respond to oxidation or
reduction processes that allows for the regulation of their activ-
ities (42). There are a number of reports that show interaction
of human peroxiredoxin 1 with the nucleus. This binding
capacity and the downstream effects on transcriptional regula-
tion can be either dependent or independent of the peroxidase
activity of the protein, and it has been suggested that apart from
acting as an antioxidant the protein can act as a chaperone to
stabilize other DNA-binding factors (43–45).
The broad distribution of PfnPrx across the P. falciparum
genome suggests that it plays a general role across the chromo-
somes and it could possibly be associated with nucleosomes.
Studies on humans, Drosophila, and worms have shown that
nucleosome occupancy increases in coding regions and that
this is independent of transcriptional status (46–48). In addi-
tion, our previous studies on core histone H3 demonstrated a
slight enrichment in the coding body of genes similar to that
observed for PfnPrx. Such a similar enrichment profile is con-
sistent with a potential association of PfnPrx with nucleosomes
(49). Due to its very highly positively charged C terminus,
PfnPrx could potentially interact directly with the phosphate
backbone of the DNA, without the need to link through an
interacting partner. It is indeed well documented that the
lysine-rich C-terminal tails of linker histone H1s bind directly
to the linker DNA entering and exiting a nucleosome leading to
the formation of higher order folding states of chromatin (50,
51). Although linker histones of multicellular eukaryotes dis-
play a tripartite structure made up of a conserved globular
domain flanked by two less structured N- and C-terminal
domains, their counterparts in several protists and bacteria
only contain the lysine-rich C terminus (reviewed in Ref. 52). It
is worth mentioning that although H1-like basic proteins have
been found in dinoflagellates (53) and ciliates (54), none have
been identified for any of the apicomplexans, also members of
the alveolates family. It is tempting to speculate that the lysine-
richC terminus of PfnPrx could potentially play a similar role in
chromatin structure; however, our attempts to recombinantly
express the full-length PfnPrx or its C-terminal tail to investi-
gate a potential association with nucleosomes in vitro have
unfortunately been unsuccessful so far. In any case, if PfnPrx is
involved in the protection of the genome against oxidative
stress, the pairing of a peroxiredoxin domainwith a highly basic
domain suggests an ingenious means of making sure that the
enzyme would always be in a position to quickly get rid of any
oxidative insult as soon as it is produced, therefore limiting the
chances of DNA damage.
Moreover, we were unable to disrupt the PfnPrx gene
either in P. falciparum or P. berghei, suggesting that it plays
an essential role for nuclear integrity or function possibly
through protecting nuclear DNA and chromatin-binding,
thiol-containing proteins from oxidative damage or because
it is intimately involved in the regulation of gene expression.
In conclusion, we have identified a dedicated nuclear perox-
iredoxin with broad substrate specificity that associates with
chromatin throughout the genome potentially demonstrat-
ing a specific adaptation of the malaria parasite to its hostile
environment.
FIGURE 6. PfnPrx-GFP associates with a broad range of proteins. The
immunoprecipitated proteins were grouped in categories and plotted
according the total number of peptides identified.HSPs, heat shock proteins;
RNA/DNA, proteins involved in RNA/DNAmetabolism and/or binding. The list
of proteins with accession numbers is available in the supplemental Table 1.
No GFP peptides were recovered because a P. falciparum-specific database
was used for peptide identification.
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